Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.

Scandinavian journal of infectious diseases. Supplementum - 1 Jan 2003

Montroni Maria, Monforte Antonella D'Arminio

Abstract excerpt

Witness for the prosecution: Structured treatment interruption (STI) has been considered among the possible therapeutic options for multidrug experienced HIV-infected individuals facing virological failure, since early studies suggested the possibility of viral reversion from drug-resistant mutated species to drug-sensitive wild-type virus following the release of drug pressure. However, the persistence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to DNA, Viral
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Viral

Share to Risk Assessment

Share to Treatment Failure

Share to Viral Load

Share to Virus Replication

Source

Identifiers

PMID: 15000591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.PMID 15000591Read ↗

Genotypic resistance tests for the clinical management of patients with primary HIV infection.Semantic proximity Read ↗

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.Semantic proximity Read ↗

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.Semantic proximity Read ↗

Genotypic resistance tests in the management of the HIV-infected patient at virological failure.Semantic proximity Read ↗

Genotypic resistance tests for the management of the patient failing highly active antiretroviral therapy: the resistance pattern in different biological compartments.Semantic proximity Read ↗

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.Semantic proximity Read ↗

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.Semantic proximity Read ↗

Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).Semantic proximity Read ↗

Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.Semantic proximity Read ↗

Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.Semantic proximity Read ↗

Use of genotypic assays for the detection of HIV antiretroviral resistance.Semantic proximity Read ↗

Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.